Drug companies take years, even decades and burn a tremendous amount of cash to bring a drug to the market. Some drugs pass the FDA muster easily, while some struggle through the stringent review process. However, despite the regulatory setbacks, some companies exude a steely determination to bring their drugs to market.
The company we are profiling today is Aldeyra Therapeutics Inc. (ALDX), which, being twice denied FDA approval for its first-in-class investigational eye drop, Reproxalap, isn't backing down.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com